These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32250730)

  • 21. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
    Gu L; Peng C; Zhang F; Fang C; Guo G
    Orphanet J Rare Dis; 2021 Jun; 16(1):277. PubMed ID: 34127034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifocal Micronodular Pneumocyte Hyperplasia in Tuberous Sclerosis Complex: Resolution with Everolimus Treatment.
    Lim KH; Silverstone EJ; Yates DH
    Am J Respir Crit Care Med; 2020 May; 201(10):e76. PubMed ID: 31870163
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
    Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
    Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
    Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
    Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy.
    Ruiz Guerrero E; Ledo Cepero MJ; Ojeda Claro AV; Soto Delgado M; Álvarez-Ossorio Fernández JL
    Actas Urol Esp (Engl Ed); 2021 May; 45(4):264-272. PubMed ID: 33637375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.
    Luo C; Zhang YS; Zhang MX; Chen MF; Li Y; Qi L; Li HZ; Zu XB; Cai Y
    Orphanet J Rare Dis; 2021 Jul; 16(1):299. PubMed ID: 34217357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Effectiveness of Medical Therapy and Surgical Intervention for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
    Wang Z; Zhang W; Fan Y; Zhang X
    Cancer Control; 2022; 29():10732748221140266. PubMed ID: 36471546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X; Said Q; Tran O; Krueger DA; Bissler J
    Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
    Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
    Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex.
    Colaneri M; Quarti A; Pozzi M
    Cardiol Young; 2016 Jun; 26(5):1025-8. PubMed ID: 27055516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HUGE RENAL ANGIOMYOLIPOMA (AML) IN TUBEROUS SCLEROSIS COMPLEX (TSC) WHICH IS CONTROLED BY EVEROLIMUS: A CASE REPORT].
    Kanbara T; Sakaeda K; Kusaka N; Akebi N
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):54-58. PubMed ID: 28132993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases.
    Jimenez RE; Eble JN; Reuter VE; Epstein JI; Folpe AL; de Peralta-Venturina M; Tamboli P; Ansell ID; Grignon DJ; Young RH; Amin MB
    Mod Pathol; 2001 Mar; 14(3):157-63. PubMed ID: 11266520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sporadic versus Tuberous Sclerosis Complex-Associated Angiomyolipomas: Predictors for Long-Term Outcomes following Transcatheter Embolization.
    Sheth RA; Feldman AS; Paul E; Thiele EA; Walker TG
    J Vasc Interv Radiol; 2016 Oct; 27(10):1542-9. PubMed ID: 27522275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effect of everolimus on small renal angiomyolipoma in cases of tuberous sclerosis complex-related epilepsy and subependymal giant cell astrocytoma.
    Hatano T; Yuri Y
    Asian J Surg; 2023 Mar; 46(3):1236-1237. PubMed ID: 36031512
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
    Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
    Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
    Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
    Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolution of renal angiomyolipomas in patients with tuberous sclerosis.
    van Baal JG; Smits NJ; Keeman JN; Lindhout D; Verhoef S
    J Urol; 1994 Jul; 152(1):35-8. PubMed ID: 8201681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.